DGAP-Adhoc: Elanix Biotechnologies AG annuls profit guidance and preliminary earnings for FY 2017EQS
Im Artikel erwähnte Wertpapiere: Elanix Biotech I
DGAP-Ad-hoc: Elanix Biotechnologies AG / Key word(s): Profit Warning/Change in Forecast
Elanix Biotechnologies AG annuls profit guidance and preliminary earnings for FY 2017
Additionally, other mis-management has been detected concerning outstanding loans (associated with specific conditions along with various payments without contracts) which are still under scrutiny.
Lee Ann Laurent-Applegate
Elanix Biotechnologies AG
Elanix develops and commercializes tissue regeneration products for acute wound care, dermatological and gynecological applications, and provides services in cell technologies. The company was founded in 2012 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented human progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing.
11-Feb-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Company:||Elanix Biotechnologies AG|
|Phone:||+41 22 363 66 40|
|Fax:||+41 22 363 66 41|
|Listed:||Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf|
|End of Announcement||DGAP News Service|
774211 11-Feb-2019 CET/CEST